Evidence map›Paper›PMID 26993288›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2016

Streptococcus agalactiae infection in cancer patients: a five-year study.

B A S Pimentel, C A S Martins, J C Mendonça, P S D Miranda, G F Sanches, A L Mattos-Guaraldi, P E Nagao

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Infections in Hospitalized Cancer Patients.World journal of oncology · 2021
    Review
  9. Streptococcus agalactiae strains isolated from cancer patients in Rio de Janeiro, Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021
    Article
  10. Invasive group B Streptococcus among non-pregnant adults in Brussels-Capital Region, 2005-2019.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Characterisation of bone and joint infections due to Group B Streptococcus serotype III sequence type 283.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

B A S PimentelRoberto Alcântara Biology Institute, Rio de Janeiro State University - UERJ, Rio de Janeiro, RJ-LBMFE/IBRAG, Rua São Francisco Xavier, 524 - PHLC 5º andar sala 501B- Maracanã, 20550-013, Rio de Janeiro, RJ, Brazil.
C A S MartinsNational Cancer Institute - INCA, Rio de Janeiro, RJ-HICC/HC1, Rio de Janeiro, Brazil.
J C MendonçaRoberto Alcântara Biology Institute, Rio de Janeiro State University - UERJ, Rio de Janeiro, RJ-LBMFE/IBRAG, Rua São Francisco Xavier, 524 - PHLC 5º andar sala 501B- Maracanã, 20550-013, Rio de Janeiro, RJ, Brazil.
P S D MirandaRoberto Alcântara Biology Institute, Rio de Janeiro State University - UERJ, Rio de Janeiro, RJ-LBMFE/IBRAG, Rua São Francisco Xavier, 524 - PHLC 5º andar sala 501B- Maracanã, 20550-013, Rio de Janeiro, RJ, Brazil.
G F SanchesRoberto Alcântara Biology Institute, Rio de Janeiro State University - UERJ, Rio de Janeiro, RJ-LBMFE/IBRAG, Rua São Francisco Xavier, 524 - PHLC 5º andar sala 501B- Maracanã, 20550-013, Rio de Janeiro, RJ, Brazil.
A L Mattos-GuaraldiFaculty of Medical Sciences, Rio de Janeiro State University - UERJ, Rio de Janeiro, RJ-LDCIC/FCM, Rio de Janeiro, Brazil.
P E NagaoRoberto Alcântara Biology Institute, Rio de Janeiro State University - UERJ, Rio de Janeiro, RJ-LBMFE/IBRAG, Rua São Francisco Xavier, 524 - PHLC 5º andar sala 501B- Maracanã, 20550-013, Rio de Janeiro, RJ, Brazil. pnagao@uerj.br.
Universidade do Estado do Rio de Janeiro · BRInstituto Nacional do Câncer · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the highest burden of Streptococcus agalactiae infections has been reported in industrialized countries, studies on the characterization and epidemiology are still limited in developing countries and implementation of control strategies remains undefined. The aim of this retrospective study was to assess the epidemiological, clinical, and microbiological aspects of S. agalactiae infections in cancer patients treated at a Reference Brazilian National Cancer Institute - INCA, Rio de Janeiro, Brazil. We reviewed the clinical and laboratory records of all cancer patients identified as having invasive S. agalactiae disease during 2010-2014. The isolates were identified by biochemical analysis and tested for antimicrobial susceptibility. A total of 263 strains of S. agalactiae were isolated from cancer patients who had been clinically and microbiologically classified as infected. S. agalactiae infections were mostly detected among adults with solid tumors (94 %) and/or patients who have used indwelling medical devices (77.2 %) or submitted to surgical procedures (71.5 %). Mortality rates (in-hospital mortality during 30 days after the identification of S. agalactiae) related to invasive S. agalactiae infections (n = 28; 31.1 %) for the specific category of neoplasic diseases were: gastrointestinal (46 %), head and neck (25 %), lung (11 %), hematologic (11 %), gynecologic (4 %), and genitourinary (3 %). We also found an increase in S. agalactiae resistance to erythromycin and clindamycin and the emergence of penicillin-less susceptible isolates. A remarkable number of cases of invasive infections due to S. agalactiae strains was identified, mostly in adult patients. Our findings reinforce the need for S. agalactiae control measures in Brazil, including cancer patients.

Indexed as

Streptococcus agalactiaeAdultAnti-Bacterial AgentsBrazilCombined Modality TherapyDrug Resistance, BacterialFemaleHumansMaleMicrobial Sensitivity TestsMortalityNeoplasmsPopulation SurveillanceRetrospective StudiesStreptococcal InfectionsAnti-Bacterial Agents

Identifiers

PMID26993288
OpenAlexW2297743657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.